微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2021, Vol. 13 ›› Issue (1): 71-75.doi: 10.3969/j.issn.1674-5671.2021.01.13

• 临床研究 • 上一篇    下一篇

联合检测PG、G-17和NEDD9在胃癌诊断中的价值

  

  1. 郑州人民医院院士工作站
  • 出版日期:2021-02-25 发布日期:2021-03-05
  • 通讯作者: 杨金花 E-mail13837108837@163.com
  • 基金资助:
    河南省重点研发与推广专项（科技攻关）项目（182102310355）

Value of the combined detection of pepsinogen,gastrin-17 and NEDD9 in the diagnosis of gastric cancer

  • Online:2021-02-25 Published:2021-03-05

PDF (PC)

135

赞

摘要： 目的 探讨联合检测胃蛋白酶原（PGⅠ、PGⅡ），胃泌素-17（gastrin-17，G-17）和神经前体细胞表达发育调控蛋白 9（neural precursor cell expressed developmentally down-regulated 9，NEDD9）诊断胃癌的价值。方法 收集2018年1月至2018年12月于郑州人民医院就诊的95例胃癌患者（胃癌组）及140例胃炎患者（胃炎组）的血清样本，另选择同期健康体检者100各作为正常对照。采用酶联免疫吸附法检测PGⅠ、PGⅡ、G-17和 NEDD9的表达水平。采用受试者工作特征（receiver operating characteristic，ROC）曲线评价诊断效能，logistic回归计算联合检测预测因子。结果 胃癌组和正常对照组PGⅠ、G-17和NEDD9的表达水平差异均有统计学意义（均P<0.05）；胃炎组和正常对照组PGⅡ表达水平差异有统计学意义（P<0.05）。G-17和NEDD9在早期胃癌的表达水平低于进展期胃癌（均P<0.05）。PGⅠ、PGⅡ、G-17和NEDD9诊断胃癌ROC曲线下面积（area under curve，AUC）分别为0.664、0.570、0.602、0.749，联合检测的AUC为0.827，对应的灵敏度和特异度分别为80.0%和72.9%。结论 联合检测PGⅠ、PGⅡ、G-17和NEDD9可提高胃癌的诊断效能。

关键词: 胃肿瘤, 胃蛋白酶原, 胃泌素-17, NEDD9, 诊断

Abstract: Objective To investigate the value of the combined detection of pepsinogen(PGⅠ, PGⅡ), gastrin-17(G-17) and neural precursor cell expressed developmentally down-regulated 9(NEDD9) in the diagnosis of gastric cancer. Methods The serum samples of 95 cases of patients with gastric cancer(gastric cancer group) and 140 patients with gastritis(gastritis group) from January 2018 to December 2018 in the People′s Hospital of Zhengzhou were collected, and another 100 healthy subjects in the same period were selected as normal control group. The levels of PGⅠ, PGⅡ, G-17 and NEDD9 were detected by enzyme linked immunosorbent(ELISA). The diagnostic efficiency was evaluated by receiver operating characteristic(ROC) curve analysis and the combined detection of predictors were calculated by logistic regression. Results The expression level differences of PGⅠ, G-17 and NEDD9 between the gastric cancer group and the normal control group were statistically significant(all P<0.05); The PG Ⅱ expression level difference between the gastritis group and the normal control group were statistically significant(P<0.05).The expression levels of G-17 and NEDD9 in early gastric cancer were lower than those in advanced gastric cancer(both P<0.05). The area under the ROC curve(AUC) of PGⅠ, PG Ⅱ, G-17 and NEDD9 in the diagnosis of gastric cancer were 0.664, 0.570, 0.602, 0.749, respectively, and the joint detection of AUC was 0.827, the corresponding sensitivity and specificity were 80.0% and 72.9%, respectively. Conclusion The combined detection of PGⅠ, PGⅡ, G-17 and NEDD9 can improve the diagnosis efficiency of gastric cancer.

Key words: Gastric Cancer, Pepsinogen, Gastrin-17, NEDD9, Diagnosis

中图分类号: 

  • R735.2